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Patients with Se´zary syndrome (SS), a
rare erythrodermic and leukemic form
of cutaneous T-cell lymphoma, have a
poor prognosis with a 5-year overall
survival (OS) of 20e42% and a median
OS between 2.5 and 5.0 years (Agar
et al., 2010; Bernengo et al., 1998;
Diamandidou et al., 1999; Kim et al.,
2003; Kubica et al., 2012; Talpur
et al., 2012).
Prognostic factors associated with a
worse survival reported in SS include
advanced age (Agar et al., 2010;
Diamandidou et al., 1999; Foulc
et al., 2003; Kim et al., 2003; Kubica
et al., 2012; Talpur et al., 2012), short
duration of skin lesions before diag-
nosis of SS (Foulc et al., 2003), previous
history of mycosis fungoides (Bernengo
et al., 1998; Kubica et al., 2012),
elevated serum lactate dehydrogenase
levels (Agar et al., 2010; Bernengo
et al., 1998; Diamandidou et al.,
1999; Foulc et al., 2003; Kubica et al.,
2012; Talpur et al., 2012), degree of
nodal involvement (Diamandidou
et al., 1999; Kim et al., 2003), and
factors reflecting blood tumor burden,
such as increased leukocyte counts
(Bernengo et al., 1998; Talpur et al.,
2012; Vidulich et al., 2009) or high
Se´zary cell counts (Bernengo et al.,
1998).
However, the results of these studies
are not consistent, which may be due to
different diagnostic criteria for SS, such
as inclusion of patients without a T-cell
clone in the peripheral blood, and
analysis of mixed populations of pa-
tients with SS and erythrodermic
mycosis fungoides.
Recently, we investigated the diag-
nostic significance of a large number of
immunophenotypic and molecular bio-
markers for SS in a group of patients with
SS (Boonk et al., 2016) that fulfilled theAbbreviations: DSS, disease-specific survival; OS, ov
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OrganizationeEuropean Organization
for Research and Treatment of Cancer
classification (Willemze et al., 2005).
None of these patients had a history
of mycosis fungoides. Molecular
biomarkers diagnostic for SS were copy
number alterations inMYC (gain) and/or
MNT (loss); increased expression of
DNM3, TWIST1, EPHA4, and PLS3; and
decreased expression of STAT4.
We investigated the prognostic sig-
nificance of these molecular bio-
markers and previously reported
clinical prognostic markers using the
same cohort of SS patients. Between
September 2009 and October 2013,
64 SS patients from six European
Organization for Research and Treat-
ment of Cancer centers, including
Helsinki, Finland; London, UK; Lei-
den, The Netherlands; Mannheim,
Germany; Turin, Italy; and Paris,
France were included and followed
up until January 30, 2015. At the
inclusion of the study, clinical
variables (sex, age at diagnosis, dura-
tion of skin lesions before diagnosis if
SS, lymph node involvement, leuko-
cyte count, absolute CD4 count, anderall survival; SS, Se´zary syndrome
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e 137Se´zary cell count) were recorded, and
peripheral blood samples were
collected for copy number variation
and gene expression quantitative PCR
analysis, as described previously
(Boonk et al., 2016). Lymph node
involvement was defined by presence
of enlarged lymph nodes of 1.5 cm or
larger in the longest transverse diam-
eter on computed tomography scan or
histologically confirmed lymph node
involvement.
Aberrant gene expression in the SS
samples was compared with samples
from patients with erythrodermic in-
flammatory dermatoses and healthy
control samples. Receiver operating
characteristic curve analysis was used
to determine fixed cutoff thresholds
for each individual gene expression
quantitative PCR assay with a speci-
ficity of 100% and an accuracy above
0.80. A one-tailed Mann-Whitney test
was applied to test for significant dif-
ferential expression between the SS
and erythrodermic inflammatory der-
matoses samples. P-values below
0.05 were regarded as statistically
significant. The results of aberrant
expression of the DNM3, TWIST1,
EPHA4, PLS3, and STAT4 genes were
included in the statistical analysis. A
more detailed Methods section
including these thresholds is included
in the Supplementary Materials and
Supplementary Table S1 online.
Table 1. Results of univariate and multivariate analysis for variables at Se´zary syndrome diagnosis1
Variables
Survival in Months Univariate Analysis DSS
Multivariate Analysis
DSS Univariate Analysis OS Multivariate Analysis OS
Median (Range) HR (95% CI) P-Value HR (95% CI) P-Value HR (95% CI) P-Value HR (95% CI) P-Value
Gain in copy
number of MYC
— — 0.843 — — — 0.366 — —
Yes, n ¼ 21 72 (1e129) 0.90 (0.32e2.54) — — — 0.66 (0.26e1.63) — — —
No, n ¼ 31 49 (7e86) 1 — — — 1 — — —
Loss in copy
number of MNT
— — 0.355 — — — 0.388 — —
Yes, n ¼ 35 68 (1e129) 0.61 (0.22e1.74) — — — 0.68 (0.28e1.65) — — —
No, n ¼ 17 49 (7e80) 1 — — — 1 — — —
Up-regulation
of DNM3
— — 0.337 — — — 0.008 — 0.658
Yes, n ¼ 36 71 (9e129) 0.56 (0.17e1.83) — — — 0.29 (0.12e0.72) — 0.74 (0.20e2.75) —
No, n ¼ 13 33 (1e72) 1 — — — 1 — 1 —
Up-regulation
of TWIST1
— — 0.197 — — — 0.043 — 0.342
Yes, n ¼ 32 71 (1e129) 0.48 (0.16e1.46) — — — 0.39 (0.16e0.97) — 0.57 (0.18e1.81) —
No, n ¼ 17 31 (7e80) 1 — — — 1 1
Up-regulation
of EPHA4
— — 0.312 — — — 0.311 — —
Yes, n ¼ 32 49 (7e129) 1.95 (0.53e7.12) — — — 1.70 (0.61e4.74) — — —
No, n ¼ 17 68 (1e80) 1 — — 1 — — —
Up-regulation
of PLS3
— — 0.027 — 0.006 — 0.001 — 0.002
Yes, n ¼ 32 71 (9e129) 0.29 (0.10e0.87) — 0.14 (0.03e0.56) — 0.19 (0.07e0.49) — 0.12 (0.03e0.46)
No, n ¼ 17 33 (1e72) 1 — 1 — 1 — 1 —
Down-regulation
of STAT4
— — 0.356 — — — 0.250 — —
Yes, n ¼ 44 68 (1e129) # — — — 3.28 (0.43e24.77) — — —
No, n ¼ 5 Not reached 1 — — — 1 — — —
Sex — — 0.665 — — — 0.830 — —
Female, n ¼ 25 49 (1e129) 1.21 (0.51e2.85) — — — 0.92 (0.43e1.98) — — —
Male, n ¼ 39 68 (1e115) 1 — — — 1 — — —
Age at SS diagnosis
in years, n ¼ 64
— 1.01 (0.96e1.05) 0.827 — — 1.00 (0.97e1.04) 0.850 — —
Duration of skin
lesions, n ¼ 60
— 0.98 (0.96e1.00) 0.075 0.99 (0.97e1.02) 0.447 0.99 (0.97e1.00) 0.152 — —
Lymph node
involvement
— — 0.356 — — — 0.420 — —
Yes, n ¼ 18 49 (1e74) 1.82 (0.51e6.53) — — — 1.55 (0.53e4.52) — — —
No, n ¼ 23 Not reached 1 — — — 1 — — —
Leukocyte count,
n ¼ 61
— 1.04 (1.01e1.06) 0.007 1.06 (1.02e1.10) 0.005 1.03 (1.01e1.06) 0.011 1.05 (1.01e1.08) 0.005
Absolute CD4
count, n ¼ 59
— 1 0.146 — — 1 0.265 — —
Se´zary cell count,
n ¼ 47
— 1 0.123 — — 1 0.204 — —
Abbreviations: CI, confidence interval; DSS, disease-specific survival; HR, hazard ratio; OS, overall survival; SS, Se´zary syndrome.
1Parameters significant at the 0.1 level were included in multivariate analysis.
# means no statistics can be computed.
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the Kaplan-Meier method from the date
of diagnosis until the patient’s death or
date of last follow-up. The median
follow-up time after diagnosis was 45
months (range ¼ 1e129 months).
Twenty-seven patients died during
follow-up, including 21 SS-related
deaths. The disease-specific survival(DSS) after 1, 2, 3, and 5 years was
89%, 82%, 76%, and 59%, respec-
tively, and OS was 86%, 79%, 72%,
and 49%, respectively.
Univariate analysis of parameters
with possible prognostic significance
for DSS and OS was performed using
Cox proportional hazards regression
analysis, and parameters that weresignificant at the 0.1 level were
included in a multivariate analysis
model. P-values below 0.05 were
regarded as statistically significant.
Both in univariate and multivariate
analyses, up-regulation of PLS3 was
associated with a significantly better
outcome for DSS and OS (multivariate
P ¼ 0.006 and P ¼ 0.002,www.jidonline.org 755
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756respectively). Patients with up-
regulation of PLS3 had a median sur-
vival of 71 months (range ¼ 9e129
months), compared with only 33
months (range ¼ 1e72 months) in SS
patients with normal expression of
PLS3 (Figure 1). Up-regulation of
DNM3 and TWIST1 were associated
with a better OS in univariate analysis
(P ¼ 0.008 and P ¼ 0.043, respec-
tively) but not in multivariate analysis
(P ¼ 0.658 and P ¼ 0.342, respec-
tively). Gain of MYC, loss of MNT,
up-regulation of EPHA4, and down-
regulation of STAT4 showed no
association with DSS and OS (Table 1).
Of the clinical parameters, both
univariate and multivariate analyses
showed that leukocyte count was a
significant prognostic factor for DSS
and OS (multivariate P ¼ 0.005 and P ¼
0.005, respectively), whereas sex, age,
duration of skin lesions before diag-
nosis, lymph node involvement, abso-
lute CD4 count, and Se´zary cell count
were not (Table 1).
PLS3 (T-plastin) is an actin-binding
protein that is expressed in all normal
cells of solid tissues that have a repli-
cative role, but it is normally not
expressed in T cells (Lin et al., 1999).
Expression of PLS3 has been described
as a specific marker of Se´zary cells
(Jones et al., 2012; Nebozhyn et al.,
2006). Studies investigating the mech-
anism underlying dysregulation of PLS3
expression in SS cells found no evi-
dence for PLS3mutations within coding
or promoter regions but showed signif-
icant hypomethylation of 50-cytosine-
phosphate-guanine-30 dinucleotides
95e99 within the PLS3 50-cytosine-
phosphate-guanine-30 island, which
was restricted to the PLS3þ cells (Jones
et al., 2012). Reanalysis of recently
published DNA methylation profiles
(van Doorn et al., 2016) from nine pa-
tients with SS and four healthy control
subjects included in this study
confirmed this correlation between
DNA methylation and PLS3 expression
(data not shown). A recent study found
that constitutive PLS3 expression was
associated with apoptotic resistance to
etoposide and suggested a role for cell
survival in SS (Begue et al., 2012). How
T-plastin expression is linked to a better
outcome in patients with SS is not
known and should be the subject of
further study.Journal of Investigative Dermatology (2017), VolumAlthough for a disease as rare as SS
the number of included patients is
relatively high, a limitation of this study
is a small sample size, which yielded
wide confidence intervals, and these
observations should be confirmed in an
independent study.
In conclusion, we show that up-
regulation of PLS3 is associated with a
favorable disease outcome in patients
with SS and that increased leukocyte
count is a significant adverse prognostic
factor for survival.
In all participating centers the study
was approved by their local institu-
tional ethical review boards and written
informed patient consent was obtained
(Boonk et al., 2016).
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Psoriasis vulgaris is a common inflam-
matory skin disorder that is character-
ized by abnormal epidermal
proliferation and a cellular infiltrate
including neutrophils and T cells
(Nestle et al., 2009). The number of
T helper (Th) type 1 and Th17 cells
are particularly increased in psoriatic
patients, and they are thought to
play critical roles in the pathogenesis
(Lowes et al., 2013; Nestle
et al., 2009). In addition, psoriatic
keratinocytes are morphologically
abnormal and may influence infilt-
rating T-cell function by producing
cytokines and chemokines (Lowes
et al., 2013; Nestle et al., 2009).
Serum amyloid A (SAA) is a highly
conserved, acute-phase protein that
is synthesized predominantly by the
liver and is an apolipoprotein that
is a component of high-density
lipoprotein particles in the blood
(Eklund et al., 2012). SAA isoforms
are precursors of the amyloid A
protein, a major component of the
fibrous deposit in secondary
amyloidosis associated with chronic
inflammatory disorders such as
rheumatoid arthritis (Perfetto et al.,
2010). A persistent high con-
centration of serum SAA in the
sera is considered to be a pre-
requisite for the development of
secondary amyloidosis (Gillmore et al.,
2001). In addition, SAA is known
to activate immune cells andinduce cytokines and chemokines
(Eklund et al., 2012). Furthermore, SAA
is involved in the pathogenesis of
atherosclerosis, because it is produced
and deposited in atherosclerotic lesions
(Meek et al., 1994; O’Brien et al.,
2005).
Some reports have already shown
the association between psoriasis and
SAA. Dogan et al. reported that SAA is
a more specific marker of psoriasis
rather than C-reactive protein (Dogan
and Atakan, 2010). Yu et al. showed
that SAA expression is up-regulated in
psoriatic keratinocytes and that a
Th17 cytokine, IL-17A, induces SAA
expression in the cells (Yu et al., 2015).
In addition, they also reported that
SAA induces IL-1b secretion via
nucleotide binding and oligomeriza-
tion domain-like receptor family pyrin
domain-containing 3 (NLRP3) in the
cells. These findings suggest that
keratinocyte-derived SAA is involved
in psoriatic inflammation, although the
mechanism has not yet been fully
elucidated.
We sought other molecular mecha-
nisms that might explain the SAA
increase in psoriasis patients, and we
hypothesized that some cytokines,
other than IL-17A, that are expressed
in psoriatic lesions may also induce
SAA expression in keratinocytes. We
stimulated normal human epidermal
keratinocytes (NHEKs) with panels
of cytokines, and the analyses using
real-time PCR and ELISA showedthat the Th1 cytokines IFN-g and tumor
necrosis factor (TNF)-a, in addition
to IL-17A, significantly induced SAA
expression in NHEKs; in contrast,
the Th2 cytokines, IL-4 and IL-13,
did not (Figure 1aeb). The induction
by TNF-a and IL-17A was NF-kB
dependent, whereas that by IFN-g
was signal transducer and activator
of transcription-1 dependent (see
Supplementary Figure S1aeb and
S2aeb online). Furthermore, IFN-g,
TNF-a, and IL-17A synergistically
enhanced SAA expression in NHEKs
(Figure 1c). In contrast, the addition of
IL-4 or IL-13 under the TNF-a stimu-
lation significantly suppressed the
TNF-a induced SAA expression in
NHEKs (Figure 1d).
Skin and serum samples were
collected with written informed consent
from patients with atopic dermatitis or
psoriasis and from normal healthy vol-
unteers atOkayamaUniversityHospital.
This study was approved by the Ethics
Committee of Okayama University. In
addition to the in vitro data, immuno-
histochemical analysis showed that
SAA expression was increased in the
epidermal keratinocytes and dermal
infiltrating cells in psoriatic lesions
when compared with normal skin,
as previously reported (Figure 1e and f).
ELISA analysis showed that psoriasis
patients (n ¼ 25) also had significantly
higher levels of SAA compared with
normal healthy volunteers (n ¼ 17) and
atopic dermatitis patients (n ¼ 14)
(Figure 1g). Furthermore, the serum SAA
protein levels of psoriasis patients
significantly correlated with the Psoria-
sis Area and Severity Index scores
(Figure 1h) (n ¼ 31 (the 25 subjects
shown in Figure 1g plus 6morewith SAAwww.jidonline.org 757
